Jan 22, 2018
Regeneron Announces Approval of DUPIXENT® (dupilumab) in Japan for the Treatment of Atopic Dermatitis
Dec 05, 2017
Realm Therapeutics Announces First Patient Dosed in Phase 2 Study of PR022 for the Treatment of Atopic Dermatitis
Dec 04, 2017
Tioga Pharmaceuticals' Asimadoline Reduces Nighttime Itching and Improves Disease-Related Quality of Life in Patients with Atopic Dermatitis
Dec 04, 2017
Health Canada approves Dupixent(TM), the first targeted treatment for adults with moderate-to-severe atopic dermatitis
Nov 30, 2017
US Dermatologists Delighted with Sanofi/Regeneron's Dupixent, but Increased Familiarity and Experience with Pfizer's Eucrisa May be Breeding Contempt
Nov 21, 2017
Realm Therapeutics Announces Publication of Positive Preclinical Data on PR022 in the Treatment of Atopic Dermatitis
Nov 16, 2017
Global Atopic Dermatitis Epidemiology and Patient Flow Analysis - 2017
Nov 09, 2017
Atopic Dermatitis (AD) - Market Insights, Epidemiology and Market Forecast - 2025
Nov 06, 2017
Environmental Allergies (Atopic Dermatitis) in Dogs
Oct 26, 2017
Nearly one-third of people with atopic dermatitis report depression/anxiety
Oct 11, 2017
Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis
Sep 13, 2017
Vanda's Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis
Sep 06, 2017
Medimetriks Announces Phase 2 Study Results Demonstrating Early Itch Relief for Topical PDE4 Inhibitor MM36 in Patients with Atopic Dermatitis
Sep 05, 2017
Hoth Therapeutics Inc. Announces the Addition of Dr. Andrew Herr to the Company's Technology Advisory Board
Aug 29, 2017
Global Health Solutions Announces FDA Clearance of Novel, Non-Steroidal Topical Ointment for Atopic Dermatitis
Jul 31, 2017
Glenmark Pharmaceuticals Reports Positive Data in a Phase 2a Study of GBR 830 for the Treatment of Patients with Atopic Dermatitis
Jul 25, 2017
Global Atopic Dermatitis Treatment Market - Industry Forecast to 2025 - By Mode of Administration, Distribution Channel, Drug Type & Geography
Jun 27, 2017
North America Will Continue to be the Most Lucrative Market for Atopic Dermatitis Treatment Over 2027
Jun 15, 2017
LEO Pharma Starts Phase 3 Clinical Study for Tralokinumab in Atopic Dermatitis